Company intelligence / Profile preview

Euformatics

Espoo, Uusimaa, Finland

Ownership: Private
Employees: ~16
Development stage: Other

Overview

Euformatics has achieved three consecutive years of profitable growth through 2024, with over 100% growth in patient diagnoses using their tools in 2024. The company now has more than a dozen customers on each major continent.

Therapeutic areas: OtherRare DiseasesOncology
Modalities: SoftwareComputational analysis tools
Industry: Molecular Diagnostics

Partnerships

BC Platforms (Genomics Hub partnership)Cerba (NGS test validation partnership)EMQN and UKNEQAS (external quality assessment)Appolon Biotek (distribution in France)Zahrawi Group (distribution in Bahrain, Oman, UAE)INSVAST (distribution in China)Síntese Biotecnologia (distribution in South America)SYNLAB (customer and pathogen variant surveillance partner)

Beyond the preview

Go deeper on Euformatics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Euformatics.

Explore the full profile